KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$96.97
−1.94%Research · Sep 29, 2026
Kodiak (KOD) Six-Month Wet AMD Data Raises the Bar for REGENXBIO (RGNX)
Kodiak's Zenkuda matched aflibercept in Phase 3 with 54% of patients on six-month dosing, resetting the bar that REGENXBIO's sura-vec gene therapy must clear in Q4 2026.